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Abstract 
The cytokine microenvironment modulates CD4 T cell differentiation causing the shift 
of naïve CD4 T cells into different cell subsets. This process is also regulated by modulators 
such as VIP, a neuropeptide with known immunomodulatory properties on CD4 T cells that 
exert this action through specific receptors, VPAC1 and VPAC2. Our results show that the 
pattern of VIP receptors expression ratio is modified during Th17 differentiation. In this 
report, we evaluate the capacity of VIP to modulate naïve human cells into Th17 cells in vitro 
by analyzing their functional phenotype. The presence of VIP maintains the non-pathogenic 
profile of Th17-polarized cells, increases the proliferation rate and decreases their Th1 
potential. VIP induces the up-regulation of the STAT3 gene interaction with the VPAC1 
receptor during the onset of Th17 differentiation. Moreover, RORC, RORA and IL-17A genes 
are up-regulated in the presence of VIP through interaction with VPAC1 and VPAC2 receptors. 
Interestingly, VIP induces the expression of the IL-23R gene through interaction with the 
VPAC2 receptor during the expansion phase. This is the first report that describes the 
differentiation of naïve human T cells to Th17-polarized cells in the presence of VIP and 
demonstrates how this differentiation regulates the expression of the VIP receptors. 
 
Keyword: Th differentiation, Th17, VIP, VPAC receptors. 
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Introduction 
The cytokine microenvironment and antigen-presenting cells drive in vivo 
differentiation and clonal expansion of naïve helper T cells, converting them to different 
effector cells with specific roles. Naïve human CD4 T cells can be committed to four major 
cells lineages, namely Th1, Th2, Th17 and induced regulatory T cells, on the basis of their 
cytokine and transcription factor (master regulator) signature (Zhu, 2010). The cytokine 
signature profile of Th17 cells is formed by several cytokines such as IL-17A, IL-17F, IL-21 and 
IL-22. Th17 cells are also characterized by the expression of chemokine receptors such as 
CCR6 and cytokine receptors such as IL-23R and IL-21R. Moreover, Th17 cells can secrete to 
a lesser extent IFNγ, IL-10, IL-9, IL-2 and other cytokines. The final effector functions of Th17 
cells depend on the specific combination of the cytokines produced (Zhu, 2008; Korn, 2009; 
Zhu, 2010; Ghoreschi, 2011; Hirota, 2012). Increasing evidence points to a heterogeneous 
and inherent phenotypic instability in this subset (Ghoreschi, 2011; Hirota, 2012; Sundrud, 
2013). Th17 cells are susceptible to changing to Th1, most likely due to epigenetic regulation 
(Murphy, 2010; O´Shea, 2010; Zhu, 2010; Hirota, 2012).  
The inflammatory microenvironment causes Th17 cells a separate Th subset with a 
homeostatic role, able to clear pathogens that are less efficiently resolved by Th1 or Th2 
(Chen, 2008; Acosta-Rodriguez, 2007; Cua, 2010). In contrast, Th17 cells have also been 
related to organ-specific autoimmune diseases (Korn, 2009; Hirota, 2012; Marwaha, 2012). 
In order to understand the potential role of Th17 cells in the development of massive 
inflammation and autoimmune diseases, it is important to know the regulatory mechanisms 
involved in their differentiation, proliferation and function. Inhibitory cytokines, nuclear 
receptors, metabolic sensors, inhibitors of STATs, microRNAs (Hirahara, 2010; Bi, 2012; 
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Hirota, 2012) and probably immunomodulatory neuropeptides, are able to modulate Th17 
cells. 
Vasoactive Intestinal Peptide (VIP) is a ubiquitous neuropeptide that plays important 
regulatory roles in many physiological processes through binding to its specific receptors, 
VPAC1 and VPAC2 (Couvineau, 2012; Harmar, 2012). In the immune system, VIP can 
modulate both innate and adaptive immunity, showing predominantly anti-inflammatory 
and immunomodulatory actions. In vivo mouse data indicate that VIP treatment may have a 
promising role in the treatment of inflammatory and autoimmune diseases (Delgado, 2001; 
Gomariz, 2006; Lodde, 2006; Arranz, 2008; Calafat, 2009; Smalley, 2009; Gomariz, 2010). In 
several animal models of inflammation and autoimmune diseases, it has been described that 
VIP decreases cytokine expressions related to Th17 cells (Abad, 2005; Leceta, 2007; Jimeno, 
2010). However, in vitro studies using mouse CD4+ T cells have reported that VIP plus TGFβ 
promote their differentiation to a Th17 subset in a VPAC1 dependent manner (Yadav, 2008).  
Thus far, the role of VIP in human Th17 cells remains unclear.  
Th17 cells are considered a major link between innate and adaptive immune 
responses, having a critical role in normal host defense (Graeber, 2012). This important 
scenery demands a better understanding of how these cells work and how they may be 
modulated by the microenvironment in a normal host and within the framework of 
autoimmune disease. Given the multiple effects of VIP on immune microenvironments and 
its immunomodulatory role in human autoimmune diseases, it is important to better 
understand the influence of VIP during human Th17 cell differentiation. This is the first 
report that maps the cytokine and master regulator pattern of the Th17 subset after its 
differentiation from naïve human CD4 T cells under the influence of VIP, examining their 
functionality and describing how VPAC receptors are modulated during Th17 differentiation. 
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Materials and Methods 
Isolation of naïve human T cells 
Naïve CD4+ T cells were isolated from the human cord blood from six healthy donors. 
The study was performed according to the recommendations of the Declaration of Helsinki. 
The samples were obtained after the donors had signed a written informed consent and 
were approved by the ethics committee of the Transfusion Center (Comunidad de Madrid). 
For CD4+ T cells isolation, density gradient centrifugation by Ficoll–Hypaque (Sigma Aldrich) 
and negative selection using a commercial isolation system (RosetteSep® Human CD4+ T Cell 
Enrichment Cocktail from StemCell Technologies) were combined. Naïve T cells were then 
positively isolated with a MACS Cell Isolation kit using CD45RA+ MicroBeads (Miltenyi 
Biotec). The purity exceeded 90%. 
In vitro Th17 cell polarization 
Cells were cultured at 4x104 cells/well in RPMI 1640 GlutaMAX media (Life 
Technologies) supplemented with 10% fetal bovine serum (Lonza) and 1% 
penicillin/streptomycin (Life Technologies). Cells were expanded with anti-CD3 and anti-
CD28 coated beads (Life Technologies). Three types of cultures were established: Non-
polarizing conditions; Th17-polarizing conditions in the presence of human recombinant 
TGFβ (2ng/ml) (eBioscience), human recombinant IL-23 (10ng/ml) (eBioscience), human 
recombinant IL-6 (10ng/ml) (eBioscience), human recombinant IL-1β (10ng/ml) 
(eBioscience), anti-IL-4 (2μg/ml) (BD Pharmingen) and anti-IL-12p35 (2μg/ml) (R&D System); 
and VIP/Th17-polarizing conditions as above plus 10nM of VIP (Polypeptide Group). For 
VPAC receptor agonist and antagonist studies, 10nM of agonist VPAC1 [K
15R16L27VIP (1-
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7)/GRF (8-27)] or agonist VPAC2 (RO 25-1553) were added instead of VIP; 1μM of VPAC1 
antagonist [AcHis1DPhe2K15R16L27VIP (3-7)/GRF (8-27)] was added in addition to VIP. On day 
4 of culture, medium was replaced with one containing the recombinant cytokines, peptides 
and antibodies corresponding to each treatment but without anti-CD3 and anti-CD28 to 
avoid overstimulation. 
RNA Extraction and Semi-quantitative real-time PCR 
For total RNA extraction we used the TriReagent method (Sigma Aldrich). Total RNA 
(2μg) was reverse transcribed using a High Capacity cDNA Reverse Transcription Kit (Life 
Technologies). Semi-quantitative real-time Polymerase Chain Reaction (PCR) analysis for all 
molecules tested was performed using TaqMan Gene Expression Master Mix (Life 
Technologies), with the exception of IL-22, which was tested using SYBR® Green PCR Master 
Mix (Life Technologies) (Table 1). β-Actin was used as an endogenous reference gene. For 
each sample, we compared the amount of target mRNA normalized to the endogenous 
reference, using the formula 2-ΔΔCt.  
Measurement of Cytokines 
Cells were restimulated on day 7 with 20ng/ml Phorbol Myristate Acetate (PMA) and 
0.5μM ionomycin (Sigma Aldrich) for 6 hours. After stimulation, the levels of IL-17A, IL-21, IL-
22, IFNγ, IL-9, IL-2 (eBioscience) and IL-10 (Diaclone) were analyzed by Enzyme-Linked 
ImmunoSorbent Assay (ELISA).  
Measurement of BrdU incorporation 
Cell proliferation was determined by incorporation of Bromodeoxyuridine (BrdU) into 
DNA using the Cell Proliferation Assay Kit (Roche). On days 4 and 7 of culture, cells were 
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incubated with 10μM BrdU for 24h. Absorbance at 450nm with a 690nm reference was 
measured in a plate reader (UVM 340 microplate reader, ASYS HITECH GMBH).  
Measurement of cell viability 
Viability of cells was determined by trypan blue dye exclusion assay. On day 7 of 
culture, cells were collected and incubated with trypan blue solution (1:1) and the number of 
viable and dead cells was counted. Cell viability was calculated as the relationship between 
the number of viable cells on day 7 and the total number of cells cultured. 
Flow cytometry analysis  
 After seven days of culture, cells were collected from the culture plates and labelled 
with phycoerythrin-conjugated CCR6 (clon 11A9, BD Pharmingen) at 4ºC for 30 minutes. 
Cells were washed, fixed and permeabilized with Transcription Factor Buffer Set (BD 
Pharmingen) for 50 minutes at 4ºC. Then, cells were labelled with Alexa Fluor 488-
conjugated T-bet (O4-46, BD Pharmingen), allophycocyanin-conjugated RORC (clone AFKJS-9, 
eBioscience) and Brilliant Violet 711-conjugated Ki67 (clone Ki-67, BioLegend) at 4ºC for 1 
hour in perm/wash buffer. Auto-fluorescence and isotype controls were set up to define 
non-specific fluorescence.  
Immunocytochemistry Staining 
On days 0 and 7, cell suspensions were centrifuged onto glass slides (50.000 
cells/glass slide), dried and fixed.  Cells were then rehydrated and blocked with PBS 
containing 5% goat serum and 5% donkey serum. After washing, cells were incubated with 
0.02mg/mL rabbit anti–VPAC1 polyclonal antibody and/or mouse anti–VPAC2 monoclonal 
antibody (Acris Antibodies) for 1 hour. After washing, cells were incubated for 45 minutes 
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with 1μg/mL Donkey anti-rabbit IgG (H+L) Alexa Fluor 488-conjugated and goat anti-mouse 
IgG (H+L) Alexa Fluor 594-conjugated (Life Technologies). Cells were counterstained with 
1μg/ml Hoechst to visualize nuclear bodies.  
Statistical Analysis 
The t test was used to compare different cell populations, and correlations were 
conducted using Pearson´s coefficient test. Both statistical tests were done using GraphPad 
Prism Version 4.0 software (GradphPad Software).  
Results 
In vitro differentiation of Th17 cells and its maintenance by VIP 
First, we analysed the features of differentiated Th17 cells by checking protein 
expression of different cytokines in the supernatants after seven days of culture (Fig. 1A). 
Signature cytokines of the Th17 subset such as IL-17A or IL-21 were significantly increased in 
the supernatants of Th17-polarized cells. Surprisingly, the Th17-polarized cells secreted 
significantly less IL-22 compared to non-polarized cells. IFNγ levels in supernatants of Th17-
polarized cells were lower with respect to non-polarized cells. Analysis of IL-2 and IL-10 
production showed no clear differences between Th17-polarized and non-polarized cells. 
Finally, IL-9 determination showed higher protein levels in Th17-polarized cells than in the 
non-polarized cells. Thus, Th17-polarized cells in this in vitro system are characterized by 
high expression levels of IL-17A, IL-21 and IL-9 and low levels of IFNγ and IL-22. Cytokine 
levels in VIP/Th17-polarized cells were similar to Th17-polarized cells, with the exception of 
IL-17A protein, which was lower in the Th17-polarized cells in the presence of VIP. 
Nevertheless, IL-17A levels were significantly higher in these cells than in non-polarized cells.  
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We analyzed the mRNA expression of IL-21R, IL-23R and IL-12Rβ2 (Fig. 1B). Regarding 
IL-21R expression, similar levels of expression were determined in all cases. Our data also 
showed higher IL-23R mRNA levels in Th17-polarized cells compared to non-polarized cells. 
VIP significantly increased the expression of IL-23R. IL-12 receptor expression was 
determined by the analysis of the IL-12Rβ2 subunit. The results showed significantly 
decreased IL-12Rβ2 expression in both Th17- and VIP/Th17-polarized cells.  
We also examined the mRNA expression of transcription factors of different Th 
subsets (Fig. 2). Results showed that RAR-related Orphan Receptor C (RORC), RORA and Aryl 
hydrocarbon Receptor (AhR) expression were higher in Th17-polarized than in non-polarized 
cells. Analysis of STAT3 expression did not show significant differences between the two 
conditions. In contrast, Foxp3 and T-box transcription factor (Tbx21/T-bet) expression was 
lower in Th17-polarized than non-polarized cells. Interestingly, VIP/Th17-polarized cells 
showed higher RORC, RORA and STAT3 expression than Th17-polarized cells. In summary, 
the presence of VIP during human Th17 differentiation could maintain their Th17 
commitment and significantly enhances IL-23R, RORC, RORA and STAT3 expression.  
Functional features of in vitro human Th17-polarized cells: Modulation by VIP 
Recent studies have begun to shed light on the heterogeneity (pathogenic or non-
pathogenic phenotype) and inherent phenotypic instability of Th17 subsets (McGeachy, 
2007; Murphy, 2010; Sundrud, 2013). Different profiles of cytokines expressed by Th17 cells 
are related to the pathogenic or non-pathogenic phenotype of these cells, thus we 
determined the correlations between several cytokines, associated with pro-inflammatory or 
anti-inflammatory Th17 profiles, with IL-17 and RORC (Fig. 3). IL-17A levels were positively 
correlated with IL-10, IL-9 and IL-21 levels, either in the presence or absence of VIP, with a 
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Pearson’s coefficient (r) near 1.0 in all cases. Negative correlations were seen between IL-2 
and IL-17A and between RORC and IL-22 (Pearson’s coefficient close to -1) in both cases. On 
the other hand, considering the balance of Th17/Th1, only when VIP is added to the cultures, 
IFNγ and Tbx21 expressions were negatively correlated to the expression of IL-17A and 
RORC, respectively (Fig. 4A). Flow cytometric analysis of RORC- and T-bet-expressing cells on 
day 7 showed that 78.8% and 81.7% of Th17- and VIP/Th17-polarized cells, respectively, 
were positive for RORC but negative for T-bet (Fig. 4B). A small percentage of RORC+/T-bet+ 
double positive cells was detected, which was lower in VIP/Th17-polarized (1,87%) than in 
Th17-polarized cells (3,85%). 
Functional features of Th cells depend on their proliferation and homing capacity. 
Hence, we also tested their proliferation rate by analysing the incorporation of BrdU into 
DNA on days 4 and 7 (Fig. 5A). There were no significant differences between Th17- and 
VIP/Th17-polarized cells on day 4, whereas on day 7 Th17-polarized cells had higher levels of 
BrdU incorporation than non-polarized cells. Interestingly, at day 7, the presence of VIP 
during the Th17 polarization of the naïve Th cells increased their proliferation rate compared 
to non-polarized and Th17-polarized cells. Also, we determined the cell viability of our cells 
on day 7. No differences were found in the cell viability between non-polarized cells and 
Th17-polarized cells, and between Th17-polarized cells and VIP/Th17-polarized cells (Fig.5A). 
In addition, we measured the proportion of cells that expressed RORC and the proliferation 
marker Antigen KI-67 (Ki67) by flow cytometric analysis (Fig. 5B). Around 83% of total cells 
were double positive for RORC and Ki67. Almost all RORC cells were actively proliferating. No 
differences were observed when VIP was added to the cultures. 
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We explored the homing capacity of the Th17 cells by studying the expression of the 
chemokine receptor CCR6. Double positive RORC/CCR6 cells were detected on Th17-
polarized (74.8%) and in VIP/Th17-polarized cells (77.3%) (Fig. 5C) indicating that Th17-
polarized cells have a migration capacity and that VIP preserves their homing capacity. 
Switch in the expression pattern of VIP receptors with Th17 polarization 
We tested the expression of VPAC1 and VPAC2 receptors for VIP. As Fig. 6A shows, 
VPAC1 expression is down-regulated during T cell culture under CD3 and CD28 stimulation 
whereas VPAC2 expression is maintained with Th17 polarization. The ratio between mRNA 
expression of VPAC2 and VPAC1 receptors was significantly increased in activated/expanded 
cells with respect to CD4+CD45RA+ T cells after seven days of culture. This ratio was close to 
1.0 in non-polarized cells; however, it was significantly increased in Th17- and VIP/Th17-
polarized cells. VIP/Th17-polarized cells increased the expression of both receptors but not 
significantly. The VPAC1 increase in VIP/Th17-polarized cells was of greater magnitude 
compared to the VPAC2 increase; consequently the VPAC2/VPAC1 ratio was significantly less 
than in Th17-polarized cells. VPAC receptor expression was corroborated at the protein level 
by immunocytochemical analysis (Fig. 6B). We detected expression of both VPAC1 and VPAC2 
in naïve Th cells and Th17-polarized cells. No staining was observed when isotype controls 
were used. These results confirmed the receptor pattern observed at the mRNA level. In 
summary, VPAC1 could be the main receptor involved during the onset of Th17 generation, 
whereas Th17 differentiation induces a switch on VIP receptors, with VPAC2 being the main 
receptor expressed after the differentiation of Th17 cells. 
In order to test the specificity of VPAC receptor involvement in the effect of VIP 
during Th17-polarization, we used specific agonists and one antagonist (Fig. 7). The presence 
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of VPAC1 antagonist during the differentiation of VIP/Th17 cells significantly reduced IL-17A, 
STAT3 and RORC VIP-stimulated mRNA expression. RORA was also reduced but not 
significantly. In Th17-polarized cells, the VPAC1 agonist significantly augmented IL-17A, 
RORC, RORA and STAT3 mRNA expression compared to Th17-polarized cells. In Th17-
polarized cells, the VPAC2 agonist induced an increase in the expression of mRNA in all 
molecules tested with the exception of STAT3.  
Discussion 
 Th17 cells were initially described as the key pathogenic element in several 
autoimmune diseases (Korn, 2009; Hirota, 2012; Marwaha, 2012). Conversely, new evidence 
suggests that, depending on the microenvironment, Th17 cells can alter their differentiation 
program, inducing either protective/anti-inflammatory or pro-inflammatory responses 
(Ghoreschi, 2011; Marwaha, 2012; Sundrud, 2013). How different factors of an inflammatory 
microenvironment can modulate differentiation, function or pathogenicity of human Th17 is 
still unclear and requires further attention. Given the known immunomodulatory and anti-
inflammatory role of VIP in several inflammatory and autoimmune disorders, we report for 
the first time the influence of this neuropeptide on human Th17 cell differentiation and 
function.  
Many studies have examined Th17 differentiation in vitro, both in mouse and human. 
Although there are discrepancies between different authors about the importance of some 
cytokines, it is clear that IL-6, IL1-β and IL-21 are involved in human Th17 differentiation 
(Korn, 2009; Ganjalikhani, 2011; Hirota, 2012). The implication of TGFβ in this process is 
associated with the pathogenicity, or lack thereof, of Th17 cells. This cytokine is linked with 
the differentiation of a non-pathogenic phenotype (McGeachy, 2007; Ghoreschi, 2011; 
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Zuñiga, 2013). Despite its implications in their potential pathogenicity (Lee, 2012), the 
presence of IL-23 is necessary for the stabilization of Th17 cells (Korn, 2009). In this sense, 
McGeachy et al. suggest that when cells are polarized in the presence of TGFβ, IL-6 and IL-
23, the effect of the former are predominant with respect to IL-23 and this effect is related 
with a non-pathogenic phenotype (McGeachy, 2007). For these reasons, we used IL-6, IL1-β, 
IL-21, TGFβ and IL-23 in our in vitro human Th17 differentiation model. 
As expected, a main increase in IL-17A and IL-21 cytokines and the transcription 
factors RORC and RORA were confirmed in Th17-polarized cells. Indeed, a positive 
correlation between IL-21 and IL-17A was observed. In contrast, a decrease in IL-22 levels 
was detected in Th17-polarized cells. A negative correlation between IL-22 and RORC was 
observed in Th17-polarized cells. In accordance with these findings, it has been described 
that T cells re-stimulated in the presence of TGFβ and IL-6 did not induce IL-22 expression 
(McGeachy, 2007). Related to IL-2 expression, results showed a slight tendency to decrease 
IL-2 secretion and a negative correlation between IL-2 and IL-17 in Th17-polarized cells. IL-2, 
a survival factor of Th cells, inhibits Th17 differentiation at early stages, but can expand Th17 
cells at a late stage (Amadi-Obi, 2007; Korn, 2009). Their high expression levels in Th17 cells 
have been associated with a pathogenic phenotype in these cells (Gohreschi, 2011; Zuñiga, 
2013). Meanwhile, similar levels of IL-10 were detected in non-polarized and Th17-polarized 
cells. In contrast, the IL-9 levels were increased in Th17-polarized cells. A positive correlation 
between IL-10 and IL-17 and between IL-9 and IL-17 levels appears in Th17-polarized cells. 
The production of IL-10 and IL-9 by Th17 cells points to their potential non-pathogenic/anti-
inflammatory phenotype (Gohreschi, 2011; Zuñiga, 2013). In this sense, Th17 cells activated 
in the presence of TGFβ and IL-6 secrete IL-17 and IL-10, suggesting a potential regulatory 
function for these cells or a possible regulatory mechanism to counteract their pathogenic 
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potential (McGeachy, 2007). In addition, it has been demonstrated that IL-9 non-secreting 
Th17 cells were more pathogenic than IL-9 secreting Th17 cells (Beriou, 2010). In regards to 
the cytokine receptor, we observed higher IL-23R mRNA levels in Th17-polarized cells than in 
non-polarized cells. Therefore, Th17-polarized cells are able to respond to IL-23, the cytokine 
necessary for the stabilization of this subset. Different reports relate IL-23R expression to the 
pathogenicity of Th17 cells (Lee, 2012; Zuñiga, 2013). However, this receptor is not exclusive 
of pathogenic Th17 cells, but the overexpression of IL-23R is related to a pathogenic/pro-
inflammatory phenotype (Ghoreschi, 2011; Lee, 2012; Zuñiga, 2013). Aside from RORC and 
RORA, another transcription factor closely related to the Th17 subset is AhR. As has been 
previously described, AhR expression was significantly increased in Th17-polarized cells 
(Veldhoen, 2008). Ghoreschi, et al. showed that Th17 cells, differentiated in the presence of 
TGFβ, express high levels of AhR and demonstrated that these cells are less pathogenic than 
Th17 cells differentiated in the absence of TGFβ that do not express AhR (Ghoreschi, 2011). 
Taking into account all of these data, our data show that Th17 cells differentiated in our 
culture conditions present the following characteristics of a non-pathogenic/anti-
inflammatory profile: an increase in IL-9 secretion, AhR expression and a decrease in IL-22 
and IFNγ secretion and T-bet expression. In addition, we demonstrated positive correlations 
between IL-17 and cytokines related to non-pathogenic phenotype (IL-17 and IL-10, IL-17 
and IL-9) and a negative correlation with pathogenic indicators (IL-17 and IL-2, RORC and IL-
22).  
From the standpoint of plasticity and heterogeneity, Th17 cells are closely related to 
the Th1 subset (Murphy, 2010; O´Shea, 2010). The levels of IFNγ and Tbx21 were decreased 
in Th17-polarized cells. It has been suggested that TGFβ downregulates Tbx21 expression 
and as a consequence IFNγ expression (Ghoreschi, 2011; Zuñiga, 2013), decreasing IFNγ+/IL-
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17+ double-secreting Th17 cells (Ganjalikhani, 2011). A low percentage of RORC
+/T-bet+ 
double-positive cells was observed in our cultures. Moreover, IL-12Rβ2 expression was 
significantly decreased after Th17-differentiation, in agreement with previous reports (Korn, 
2009). On the basis of all of these findings, we document a decrease in Th1 profile of Th17 
cells polarized in these in vitro conditions. This fact is related with a non-pathogenic/anti-
inflammatory phenotype, since conversion of Th17 to a Th1 phenotype can promote the 
pathogenic potential of these cells.  
Proliferation analysis showed a greater proliferation in Th17-polarized cells than in 
non-polarized cells on day 7. In addition, we confirmed that around 83% of total cells were 
double positive for RORC and Ki67. Therefore, in our culture conditions, almost all RORC cells 
were actively proliferating. Although it has been described that Th17 cells have a low ability 
to proliferate and to produce IL-2 in response to combined CD3 and CD28 stimulation 
(Santarlasc, 2012), Th17 cells polarized in our cultures show high proliferation rate and 
secreted IL-2. This fact could be explained in part by the increase in the expression of IL-23R 
during differentiation process and their capacity to answer to IL-23, cytokine associated with 
the expansion of Th17 subset (Zhu, 2008). In addition, differences in culture conditions such 
as the stimulation conditions, the cytokines used in the polarization, the time of the culture 
or the method used to check the proliferation, could explain this discrepancy.  
In addition to previous analyses, we checked the homing capacity of the Th17 cells 
through the analysis of the expression of the chemokine receptor CCR6, which is the most 
important homing receptor for Th17 cells. This chemokine receptor allows their migration to 
an inflammatory microenvironment in response to CCL20 (Acosta-Rodriguez, 2007; Korn, 
2009). Double-positive RORC/CCR6 cells were detected in Th17-polarized cells. These results 
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indicate that Th17 cells polarized in our in vitro culture conditions have the capacity of 
respond to CCL20. 
VIP plays several modulatory roles in many physiological processes in the immune 
system. It shows predominantly anti-inflammatory and immunomodulatory actions, 
modulating the innate and the adaptive responses. Related to Th subsets, it has been 
described that VIP is able to modulate Th1, Th2 or iTreg cells (Gomariz, 2006; Gutiérrez-
Cañas, 2008; Jimeno, 2010; Jimeno, 2011). In vitro and ex vivo studies with mice 
demonstrated that VIP can promote the Th17 subset, over the Th1 subset (Yadav, 2008; 
Jimeno, 2011). Our results show that in human VIP/Th17-polarized cells the IL-17A secretion 
was decreased. This decrease in IL-17A protein expression in the presence of VIP has been 
described previously (Jimeno, 2011). However, results show that VIP induces the expression 
of IL-17A mRNA levels. Post-transcriptional regulation mechanisms could be involved in this 
discrepancy, but future studies are needed to clarify this. Related to cytokine receptor 
expression, IL-23R mRNA expression was increased in the presence of VIP. As mentioned 
above, the expression of IL-23R indicates that cells are able to respond to IL-23, the cytokine 
necessary for the stabilization of this subset. Although several reports have associated the 
overexpression of IL-23R with pathogenicity of Th17 cells (Ghoreschi, 2011; Lee, 2012; 
Zuñiga, 2013), the expression of IL-23R is not exclusive of pathogenic Th17 cells. In this 
sense, the increase in IL-23R expression shown in the presence of VIP could indicate a 
greater stabilization of Th17-polarized cells generated in these culture conditions. On the 
other hand, our results show that RORC, RORA and STAT3 were significantly increased in the 
presence of VIP. Since the lineage-defining transcription factors of the Th17 cells are RORC 
and RORA (Yang, 2008), the increase in expression of both in the presence of VIP show that 
this neuropeptide promotes Th17 differentiation in our culture conditions. In addition, it has 
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been described that STAT3 is related to IL-23R, RORC and RORA expression (Harmar, 2012). 
For this reason, an increase in STAT3 expression in cells treated with VIP could indicate that 
VIP supports Th17 cells. On the other hand, in the presence of VIP, no differences in the 
expression of IL-22 were detected in the Th17-polarized cells, but were significantly less 
expressed than in non-polarized cells. In this sense, it has been reported that VIP decreases 
IL-22 production by Th17 cells (Ding, 2012) but, conversely, increases IL-22 expression during 
mouse Th17 differentiation (Yadav, 2008). Regarding the heterogeneity of Th17 cells, it has 
been described that VIP promotes Th17 over the Th1 subset in mouse (Jimeno, 2011) and in 
a model of autoimmune diabetes (Jimeno, 2010). A positive correlation between IFNγ and IL-
17A and between Tbx21 and RORC was observed in Th17-polarized cells. This may indicate a 
slight tendency toward a Th1 shift in the present culture conditions. Recent studies highlight 
the importance of the plasticity of Th17 cells in the Th1 phenotype (Lee, 2008; Lexberg, 
2010; Hirota, 2012; Sundrud, 2013). Conversion of Th17 to the Th1 phenotype might 
contribute to the pathogenic potential of these cells. Analysis of the Th17/Th1 profile in the 
presence of VIP showed that these correlations were negative in VIP/Th17-polarized cells, 
which also show a decrease in RORC+/T-bet+ double-positive cells, indicating that in the 
presence of VIP, Th17 cells are less prone to differentiate to a Th1 pathogenic phenotype 
(Fig.8). 
It has been shown that VIP inhibits proliferation of human CD4+ T cells and mouse 
erythrocyte-depleted spleen cells (Delgado, 1996; Jimeno, 2011). However, in human, VIP 
can act as an inductor or inhibitor of proliferation in different human cells (Harmar, 2012). 
Our results using BrdU indicate that VIP promotes the proliferation rate of Th17-polarized 
cells at day 7. Moreover, we determined the cell viability on day 7 and found no differences 
between Th17-polarized cells and VIP/Th17-polarized cells. Thus, we confirmed that the VIP 
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effect was due to a proliferation increase and not a cell viability increase. On the other hand, 
the analysis of Ki67/RORC double-expressing cells showed that this expression in the 
presence of VIP is not altered. This is not unexpected since BrdU is incorporated into DNA 
only during the S phase of the mitotic process whereas Ki67 is expressed for its whole 
duration. Therefore, a possible effect of VIP only during the S phase could be lost in Ki67 
expression analyses given the high expression levels of this protein in Th17-polarized cells. In 
summary, the presence the VIP caused an increase in the proliferation rate of Th17-polarized 
cells (Fig. 8). This result is according to above mentioned results and they indicate that VIP 
promotes the Th17 population in our culture conditions. These findings are consistent with 
previous in vitro and ex vivo studies in mice that demonstrated that VIP can promote the 
Th17 subset (Yadav, 2008; Jimeno, 2011). In addition, studies with different mice models of 
autoimmune diseases have shown that VIP is able to promote the Th17 differentiation in 
vivo (Abad, 2005; Leceta, 2007). Taking account, that there are endogenous sources of VIP, 
as nerves fibres and immune cells, this neuropeptides could modify human Th17 profile in 
vivo. 
In relation to VIP receptor expressions, CD4+ T cells have been studied previously 
(Vomhof-DeKrey, 2008; Dorsam, 2011). Our results demonstrate the interesting finding that 
the VPAC receptor pattern changed in our cultures. Unlike naïve Th cells, Th17-polarized 
cells predominantly express the VPAC2 receptor. It has been described that naïve human and 
mouse CD4+ T cells predominantly express the VPAC1 receptor and after clonal expansion 
there is a down-regulation of this receptor (Vomhof-Dekrey, 2008; Dorsam, 2011). Changes 
in the pattern of VIP receptors with the degree of activation/maturation of the cells have 
been described (Juarranz, 2008; Vomhof-Dekrey, 2008; Dorsam, 2011). Although an increase 
in the VPAC2/VPAC1 ratio was observed in non-conditioned cells, this increase was 
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significantly higher in Th17-polarized cells. In addition, Yadav et al. noted that VIP-induced 
Th17 differentiation was mainly mediated through the VPAC1 receptor (Yadav, 2008). In 
addition, in our cultures, the high levels of VPAC1 expression in naïve cells may be involved in 
the differentiation process. Differential expression of VIP receptors in human Th cells is 
poorly understood and future studies are needed to clarify whether Th17-polarized cells 
express more VPAC2 or VPAC1. On the other hand, we tested the specificity of VIP receptors 
involvement in the effect of VIP during Th17-polarization using specific agonists and 
antagonist (Fig. 8). The specific agonists for VPAC1 and VPAC2 were previously and 
extensively used with a high affinity for each receptor subtype (Couvineau, 2012; Harmar, 
2012). The specific VPAC1 antagonist, [AcHis
1DPhe2K15R16L27VIP (3-7)/GRF (8-27)], has 200 to 
1000-fold greater affinity for the human VPAC1 than for the human VPAC2 receptor. 
However, it does not stimulate the adenylate cyclase activity of any membrane preparation 
in a concentration range from 0.1 to 10.000 nM (Gourlet, 1997; Ceraudo, 2012). As a 
consequence, this antagonist does not induce a biological effect per se (Baun, 2011). By 
examining the functionality of VPAC receptors, we can conclude that the expressions of 
important molecules of Th17 cells such as RORA, RORC or IL-17A are up-regulated by VIP 
through VPAC1 and VPAC2 receptors. Meanwhile, VIP exerts up-regulation of IL-23R, a crucial 
molecule for Th17 stabilization in the late stages of Th17 differentiation, through the VPAC2 
receptor. However, the VPAC1 receptor was shown to mediate STAT3 up-regulation, 
according to a previous study that describes the effect of VIP on STAT3 in human renal cell 
carcinoma (Vacas, 2012).  
In conclusion, our results demonstrate that VIP may maintain the non-
pathogenic/anti-inflammatory profile of human Th17 cells; increase their proliferation rate; 
and reduce the Th1 potential of these cells. In addition, Th17 differentiation induces a switch 
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in VPAC receptor expression pattern. These results highlight a novel translational view in 
inflammation/autoimmune diseases, which adds new reasons to consider VIP as a 
therapeutic agent with great potential in the clinical setting.  
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Figure Legends 
Figure 1. Cytokine profile and cytokine receptor expressed by human Th17- and VIP/Th17-
polarized cells. (A) Protein expression of IL-17A, IL-21, IL-22, IFNγ, IL-2, IL-10 and IL-9 was 
analyzed in culture supernatants by ELISA. Values were corrected considering the final 
volume of supernatants and the number of viable cells of each sample. (B) mRNA expression 
of IL-21R, IL-23R and IL-12Rβ2 was determined by real-time PCR on day 7. Data were 
analyzed normalizing with β-Actin mRNA expression and compared with the mRNA 
expression of CD4+CD45RA+ T cells (which was set at 1). Data are the mean ± SEM of six 
different cultures, performed in duplicate or triplicate. * P<0.05, ** P<0.01, *** P<0.001 
non-polarized cells versus the other conditions, and # P<0.05, ### P<0.001 Th17-polarized 
versus VIP/Th17-polarized. 
Figure 2. Transcription factors expressed by human Th17- and VIP/Th17-polarized cells. 
mRNA expression of RORC, RORA, AhR, STAT3, Foxp3 and Tbx21 was determined by real-
time PCR on day 7. Data were analyzed normalizing with β-Actin mRNA expression and 
compared with the mRNA expression of CD4+CD45RA+ T cells (which was set at 1). Data are 
the mean ± SEM of six different cultures, performed in duplicate or triplicate. * P<0.05, ** 
P<0.01, *** P<0.001 non-polarized cells versus the other conditions, and # P<0.05, ## 
P<0.01, ### P<0.001 Th17-polarized versus VIP/Th17-polarized.  
Figure 3. Relationships between mRNA expression of several cytokines and master 
regulators suggest a non-pathogenic Th17 phenotype. Correlation between mRNA 
expression of IL-10 and IL-17A, IL-9 and IL-17A, IL-21 and IL-17A, IL-2 and IL-17A, and RORC 
and IL-22 were determined by real-time PCR on day 7 of culture after PMA and ionomycin 
stimulation for six hours. Data were analyzed normalizing with β-Actin mRNA expression and 
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compared with the mRNA expression of CD4+CD45RA+ T cells (which was set at 1). Data are 
the mean ± SEM of six different cultures performed in triplicate. Pearson’s coefficients (r) are 
shown. 
Figure 4. Relationships between specific cytokines and master regulators for Th17 and Th1 
subsets under VIP influence. (A) Correlation between mRNA expression of IFNγ and IL-17A 
or Tbx21 and RORC was determined by real-time PCR on day 7 of culture after PMA and 
ionomycin stimulation for six hours. Data were analyzed normalizing with β-Actin mRNA 
expression and compared with the mRNA expression of CD4+CD45RA+ T cells (which was set 
at 1). Data are the mean ± SEM of six different cultures performed in triplicate. Pearson’s 
coefficients (r) are shown. (B) T-bet and RORC expression was determined by flow cytometry 
analysis. After 7 days of culture, cells were labelled with Alexa Fluor 488-conjugated T-bet 
and allophycocyanin-conjugated RORC. Figure shows a dot plot analysis indicating T-bet 
expression versus RORC expression in Th17-polarized and VIP/Th17-polarized cells. One 
representative experiment of three is shown.  
Figure 5. Influence of VIP on proliferation and homing capacity of Th17-polarized cells. (A) 
Cell proliferation rate and cell viability were tested in the different cell populations. A 
colorimetric method based on BrdU incorporation into DNA during cell division was used in 
the cultures on day 4 and 7. According to the blank and background values, absorbance data 
were converted to percentages considering the mean of absorbance data of Th17-polarized 
cells of each sample as 100%. Final results correspond to the mean ± SEM of three different 
cultures. * P<0.05, *** P<0.001 non-polarized cells versus the other conditions and #P<0.05, 
### P<0.001 Th17-polarized versus VIP/Th17-polarized. Viability of cells was determined by 
trypan blue dye exclusion assay on day 7 of culture in the different cell populations. Cell 
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viability was calculated as the relationship between the number of viable cells on day 7 and 
the total number of cells cultured. Values were adjusted considering the number of wells 
cultured for each sample. (B) Th17-polarized cells proliferation was also tested by flow 
cytometry analysis studying Ki67 and RORC expression. After seven days of culture, cells 
were labelled with Brilliant Violet 711-conjugated Ki67 and allophycocyanin-conjugated 
RORC. Figure shows a dot plot analysis indicating Ki67 expression versus RORC expression 
and a histogram analysis indicating Ki67 expression. One representative example of three is 
shown. (C) Homing capacity of Th17-polarized cells was studied analyzing CCR6 expression 
by flow cytometry analysis. After seven days of culture, cells were labelled with 
phycoerythrin-conjugated CCR6 and allophycocyanin-conjugated RORC. Figure shows a dot 
plot analysis indicating CCR6 expression versus RORC expression. One representative 
experiment of three is shown. 
Figure 6. Switch in the expression pattern of VPAC receptors during human Th17 
differentiation. (A) mRNA expression of VPAC1 and VPAC2 was determined by real-time PCR 
on day 0 for CD4+CD45RA+ T cells and on day 7 of culture after PMA and ionomycin 
stimulation for six hours for non-polarized cells, Th17-polarized and VIP/Th17-polarized cells. 
Data were analyzed normalizing with β-Actin mRNA expression and compared with VPAC2 
mRNA expression of non-polarized cells (which was set at 1). Individual mRNA expression 
and the ratio between mRNA expression of VPAC1 and VPAC2 are shown. Data are the mean 
± SEM of five different cultures performed in triplicate. ** P<0.01, *** P<0.001 
CD4+CD45RA+ T cells versus the other conditions, ### P<0.001 non-polarized cells versus 
Th17-polarized cells and δδδ P<0.001 Th17-polarized versus VIP/Th17-polarized. (B) Protein 
expression of VPAC1 and VPAC2 receptors was analyzed by immunofluorescence staining in 
CD4+CD45RA+ T cells on day 0 and Th17-polarized cells on day 7. Nuclei were counterstained 
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with Hoechst (blue) and receptors were stained with Alexa Fluor 488-conjugated secondary 
antibody (green) and Alexa Fluor 594-conjugated secondary antibody (red) for VPAC1 and 
VPAC2, respectively. One representative example of three is shown.  
Figure 7. Effect of specific agonists and antagonist for VPAC receptors during Th17 
polarization. mRNA expression of IL-17A, IL-23R, RORC, RORA and STAT3 was determined by 
real-time PCR on day 7 of culture. Different conditions for Th17-polarized cells were 
performed. Data were analyzed normalizing with β-Actin mRNA expression and compared 
with mRNA expression of non-polarized cells (which was set at 1). Data for Th17-polarized 
cells was referred as 100% and the other mRNA expression calculated as a percentage with 
respect to Th17-polarized cells. Data are the mean ± SEM of three different cultures 
performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001, Th17-polarized cells versus the 
other conditions. # P<0.05, ## P<0.01, ### P<0.001, VIP/Th17-polarized cells versus 
VIP/Th17-polarized cells + VPAC1 antagonist cells.  
Figure 8. Schematic representation of VIP effect on human Th17-polarized cells from naïve 
T cells. (A) The presence of VIP during human Th17 differentiation maintains Th17 
commitment significantly enhancing IL-23R, RORC, RORA and STAT3 expression; reduces the 
Th1 potential of Th17 cells; and increases the Th17 proliferation rate (B) VIP presence during 
human Th17 polarization up-regulates the expression of several molecules through its 
receptors VPAC1 and VPAC2. RORA, RORC or IL-17A expression are up-regulated by VIP 
through VPAC1 and VPAC2 receptors; IL-23R expression is up-regulated by VIP through the 
VPAC2 receptor; and STAT3 expression is up-regulated by VIP through VPAC1. 
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Table 1: Genes analysed by semi-quantitative real-time Polymerase Chain 
Reaction. Method, gene, genebank accession number, sequence position or 
assay location and sequence or assay ID for each primer used in the study are 
showed.  
  
Method Gene GenBank 
accession no. 
Sequence 
position/Assay location 
(TaqMan®) 
Sequence/Assay ID (TaqMan®) 
SYBR® Green β-actin E00829 1435-1535 Forward: 5'-AGAAGGATTCCTATGTGGGCG-3' 
    Reverse: 5'-CATGTCGTCCCAGTTGGTGAC-3' 
SYBR® Green IL-22 NM_020525 256-368 Forward: 5'-ACAACACAGACGTTCGTCTCATTG-3' 
    Reverse: 5'-GAACAGCACTTCTTCAAGGGTGA-3' 
TaqMan® IL-21R NM_181079.3 275 Hs00222310_m1 
TaqMan® IL-23R NM_144701.2 1037 Hs00332759_m1 
TaqMan® IL-12Rβ2 NM_001559.2 1900 Hs00155486_m1 
TaqMan® RORC NM_005060.3 182 Hs00172860_m1 
TaqMan® RORA NM_002943.3 1173 Hs00536545_m1 
TaqMan® AhR NM_001621.4 1318 Hs00169233_m1 
TaqMan® STAT3 NM_003150.3 488 Hs01047580_m1 
TaqMan® Foxp3 NM_014009.3 1004 Hs01085834_m1 
TaqMan® Tbx21 NM_013351.1 707 Hs00203436_m1 
TaqMan® IL-17A NM_002190.2 279 Hs00174383_m1 
TaqMan® IL-10 NM_000572.2 510 Hs00961622_m1 
TaqMan® IL-9 NM_000590.1 325 Hs00914237_m1 
TaqMan® IL-21 NM_021803.3 406 Hs00222327_m1 
TaqMan® IL-2 NM_000586.3 267 Hs00174114_m1 
TaqMan® IFNγ NM_000619.2 495 Hs00989291_m1 
TaqMan® VPAC1 NM_004624.3 306 Hs00270351_m1 
TaqMan® VPAC2 NM_003382.4 644 Hs00173643_m1 
TaqMan® β-actin NM_001101.3 54 Hs03023943_g1 
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